Abbie Celniker, Ph.D

Interim CEO

Abbie Celniker, Ph.D.

Interim CEO

Abbie Celniker is a partner at Third Rock Ventures, and brings 30 years of experience in R&D and senior leadership roles. Abbie focuses on the formation, development and strategy of Third Rock's portfolio companies.

Prior to joining Third Rock Ventures, she served as president and CEO of Eleven Biotherapeutics since 2011. Previously, Abbie was the president and CEO of Taligen Therapeutics from 2008 to 2011, when Taligen Therapeutics was acquired by Alexion Pharmaceuticals; following the acquisition, she served as Alexion's executive vice president, translational medicine. She has served as the global head of biologics of Novartis AG, the senior vice president of R&D strategy and operations of Millennium Pharmaceuticals, Inc. and the vice president of protein technologies of the Wyeth Research facilities.

Abbie is the chair of MassBio's board of directors, a member of the board of ImaginAb, where she was previously the chair, and a member of the scientific advisory board for Adimab. She is also a member of the board of directors of the nonprofit Unitio and T1D. She has a B.A. in Biology from the University of California, San Diego, and a Ph.D. in Molecular Biology from the University of Arizona.

Neil Exter

Interim COO

Neil Exter

Interim COO

Neil Exter is a partner at Third Rock Ventures, which he joined in 2007. Neil has more than 20 years of business development and strategic experience facilitating the successful development and implementation of operations and collaborations across the spectrum of newly emerging and established biotechnology companies. He plays an integral role in the formation, development and business strategy for portfolio companies.

Prior to joining Third Rock, Neil was chief business officer of Alantos Pharmaceuticals, leading the sale of the company to Amgen, and earlier, served as vice president for Millennium Pharmaceuticals, directing in-licensing and M&A. Earlier in his career, Neil held various executive and senior management roles within the high technology industry, including tenures at Hewlett Packard and Wang Laboratories.

Neil holds an MBA as a Baker Scholar from Harvard Business School, an M.S. from Stanford University and a B.S. from Cornell University. He is a member of the Research Committee of Children's Hospital Boston, a member of the investment committee of the Innovation Research Fund and Innovation Advisory Board at Partners Healthcare and the treasurer and a member of the board of directors of the New England Venture Capital Association. In addition, Neil serves as a member of the Advisory Council of the Electrical and Computer Engineering Department at Cornell University and the board of visitors of Columbia College.

Phil Reilly, M.D., J.D.

Interim CMO

Phil Reilly, M.D., J.D.

Interim CMO

Phil Reilly is a Venture Partner at Third Rock Ventures, which he joined in 2008 to discover, launch and build companies pursuing breakthrough treatments for rare genetic diseases. He is a highly respected clinical geneticist with an extensive track record of launching and building companies in the rare disease space.

In addition to his role at Third Rock, Phil is a trustee emeritus of Cornell University, is an Overseer of Weill Cornell Medical College, and serves on the Advisory Board to the Boston University School of Public Health. Prior to joining Third Rock, he was the chief executive officer and chairman of Interleukin Genetics, and before that, he was the executive director of the Eunice Kennedy Shriver Center for Mental Retardation. He served twice (2000 and 2003) as president of the American Society of Law, Medicine and Ethics. He is a founding fellow of the American College of Medical Genetics. He has authored or co-authored more than 100 articles in scholarly journals and has published seven books including most recently Orphan: The Quest to Save Children with Rare Genetic Disorders. Phil has held teaching positions at Tufts University School of Medicine and Harvard Medical School. He received his B.A. from Cornell University and holds an M.D. from Yale University, a J.D. from Columbia University, is a member of the Massachusetts Bar and is board certified in internal medicine and clinical genetics.

Jean-Christophe Harmange, Ph.D.

Senior Vice President of Drug Discovery

Jean-Christophe Harmange, Ph.D.

Senior Vice President of Drug Discovery

Jean-Christophe Harmange joined Goldfinch Bio after serving as Entrepreneur-In-Residence at Third Rock Ventures, where he played a leading role in launching Goldfinch Bio. Jean-Christophe brings more than 20 years of drug discovery, preclinical and early clinical development experience in large and small biopharmaceutical companies. He has led multidisciplinary discovery teams and research and development organizations in delivering several clinical development candidates. Jean-Christophe is co-inventor on more than 30 issued U.S. patents and the author of numerous publications.

Prior to his tenure at Third Rock Ventures, he served as the executive director of drug discovery at Constellation Pharmaceuticals where he was integral in building one of the premier epigenetic drug discovery organizations. He also held positions of increasing responsibility at Amgen, Eisai and Servier. Jean-Christophe received his Pharm.D. and Ph.D. in organic chemistry from the Université Paris-Sud and completed his postdoctoral training at Harvard University in Professor Yosito Kishi's laboratory.

Peter Mundel, M.D.

Senior Vice President of Biology

Peter Mundel, M.D.

Senior Vice President of Biology

Peter Mundel joined Goldfinch Bio after serving as a Consultant to Third Rock Ventures, where he played a leading role in the creation and launch of Goldfinch Bio. Peter brings more than 25 years of experience as a leader in academic research, most recently at Massachusetts General Hospital and Harvard Medical School. A major focus of Peter's work has been the development of precision therapeutics for patients with kidney diseases through a mechanistic understanding of the cell biology and pathology of the kidney, with a focus on podocytes. A pioneer of molecularly targeted treatment for proteinuric kidney disease, Peter has published more than 140 peer-reviewed manuscripts and has given numerous invited lectures nationally and internationally. He is a member of the American Society for Clinical Investigation.

As a recognized leader in the field of nephrology, Peter is the recipient of many awards including the Young Investigator Award from the American Society of Nephrology and the American Heart Association. Peter holds an M.D. from the University of Heidelberg, Germany.

Thomas Tibbitts, Ph.D.

Vice President of Computational Discovery

Thomas Tibbitts, Ph.D.

Vice President of Computational Discovery

Thomas Tibbitts comes to Goldfinch Bio from an immuno-oncology pharma company where he spent 11 years contributing to a wide range of drug discovery projects, leading structure-guided drug design as a co-inventor on a number of patents for small molecule therapeutics, two of which are currently in clinical development. As the genomics revolution took hold, he built out computational translational genomics to support clinical trials, and helped drive preclinical studies using transcriptomics to elucidate the mechanism of drug action in the tumor microenvironment and provide a basis for rational I/O drug combinations. He brings expertise in genomics, transcriptomics, informatics, software development, image analysis, protein crystallography and cloud computing. As leader of the patient registry at Goldfinch, he is passionate about leveraging his eclectic skill set and experience in genomics to bring new precision medicines to patients suffering from chronic kidney disease. Thomas holds a Ph.D. in Biophysics and has co-authored recent papers in major journals including Nature and J. Medicinal Chemistry.

Thomas Martz

Director of Corporate Development

Thomas Martz

Director of Corporate Development

Thomas Martz joined Goldfinch Bio after serving as a Senior Associate at Third Rock Ventures, where he played a leading role in the formation and launch of Goldfinch. Thomas joined Third Rock in 2015 to focus on new company creation and due diligence.

Prior to Third Rock, Thomas obtained his MBA from the MIT Sloan School of Management, where he interned in multiple strategic and business development roles at biotechnology companies including Alnylam Pharmaceuticals, Editas Medicine and Eleven Biotherapeutics. Previously, Thomas was a senior consultant in Deloitte's Life Sciences practice, where he worked with life sciences organizations and stakeholders in scientific and technological areas spanning R&D strategy and commercial operations. Before Deloitte, Thomas worked in multiple roles of increasing responsibility across biopharmaceutical research at Novartis and Biogen. In addition to his MBA, Thomas holds a B.S. in biochemistry from Boston College.

Founders and advisors

Our Founders and Advisors are world-renowned scientists and clinicians at the forefront of kidney biology, genetics, and genomics.

Joseph Bonventre, M.D., Ph.D.

Harvard Medical School, MIT, Brigham and Women's Hospital

Joseph Bonventre, M.D., Ph.D.

Samuel A. Levin Professor of Medicine at Harvard Medical School
Professor of Health Sciences and Technology, Massachusetts Institute of Technology
Chief of the Renal Division and Founding Chief of the Engineering in Medicine Division, Brigham and Women's Hospital

Joseph Bonventre's research focuses primarily on the study of kidney injury and repair and signal transduction, with a special emphasis on the role of inflammation, biomarkers and stem cells. He has more than 350 original research publications, 150 reviews/chapters and editorials and 3 books. His recent work also involves the generation of kidney organoids from stem cells and their use in kidney disease modeling. He has been elected to the American Society of Clinical Investigation (ASCI), the Association of American Physicians (AAP), the American Clinical and Climatological Association (ACCA) and the American Institute for Medical and Biological Engineering (AMBIE). He is a member of the Executive Committee of the Harvard Stem Cell Institute (HSCI).

Joseph is past-president of the American Society of Nephrology and founding member of the Board of Directors of the National Space Biology Research Institute. Joseph has chaired and served on many NIH Study Sections and is Editor of Seminars in Nephrology. He has been awarded the Osler Medal of the Royal Society of Physicians and the Bywaters Award of the International Society of Nephrology. He currently serves as a member of the NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Advisory Council.

In addition to his B.S. with distinction in Engineering Physics from Cornell, Joseph holds M.D. and Ph.D. degrees in biophysics from Harvard University. He has honorary doctorate degrees from Mt. Saint Mary's College and from the Norwegian Institute of Science and Technology in Norway. He was Director of the Harvard-MIT Division of Health Sciences and Technology for 10 years.

Anna Greka, M.D., Ph.D.

The Broad Institute, Harvard Medical School, Brigham and Women’s Hospital

Anna Greka, M.D., Ph.D.

Assistant Professor at Harvard Medical School
Institute Member at the Broad Institute of MIT and Harvard
Founding Director of Glom-NExT Center for Glomerular Kidney Disease and Novel Experimental Therapeutics

Anna Greka leads an interdisciplinary team of students, postdoctoral fellows and staff scientists in laboratories at Brigham and Women’s Hospital, Harvard Medical School and the Broad Institute working on diverse projects spanning ion channel biophysics, pharmacology, cell biology, biochemistry, imaging, in vivo studies and computational biology.

Anna currently serves as the founding director of Glom-NExT, a center focused on the development of novel experimental therapeutics at Brigham and Women's Hospital and Harvard Medical School. In addition to teaching at Harvard Medical School, she serves on the Harvard-MIT MD-PhD Leadership Council.

Anna has given numerous invited lectures nationally and internationally, and she is the recipient of several honors including a career development award from the American Society of Nephrology, a 2014 Top10 Award from the Clinical Research Council, and a 2014 Young Physician Scientist Award from the American Society of Clinical Investigation.

Anna holds an A.B. from Harvard College and an MD and PhD from Harvard Medical School and the Harvard-MIT M.D.-Ph.D. program in the Division of Health Sciences and Technology (HST). She completed her graduate work in the laboratory of David Clapham in work funded by a Howard Hughes Medical Institute (HHMI) Fellowship.

Friedhelm Hildebrandt, M.D.

Harvard Medical School, Boston Children's Hospital

Friedhelm Hildebrandt, M.D.

Warren E. Grupe Professor of Pediatrics at Harvard Medical School
Chief of the Division of Nephrology of Boston Children's Hospital

Friedhelm Hildebrandt's research work is concerned with the identification and functional characterization of recessive single-gene causes of kidney diseases in children and young adults, including nephrotic syndrome, cystic renal ciliopathies, and congenital anomalies of the kidney. His group has identified over 80 novel monogenic causative genes for chronic kidney disease and delineated the related pathogeneses.

Friedhelm has published over 280 original articles in high-ranking journals. He has received the Mead Johnson Award by the Pediatric Academic Societies, the Homer W. Smith Award by the American Society of Nephrology (ASN), the Lillian Jean Kaplan Award for PKD Research, and the Franz Volhard Award. He is a member of the American Association of Physicians (AAP), the German National Academy of Sciences, and the National Academy of Medicine (NAS/IOM), and is an alumnus investigator of the Howard Hughes Medical Institute (HHMI).

Daniel MacArthur, Ph.D.

The Broad Institute, Harvard Medical School, Massachusetts General Hospital

Daniel MacArthur, Ph.D.

Co-Director of the Medical and Population Genetics Program at the Broad Institute of MIT and Harvard
Assistant Professor at Harvard Medical School and Massachusetts General Hospital

Daniel MacArthur is a geneticist with a long-standing focus on the use of large-scale genomic data sets to improve the interpretation of human genetic variation, with a special focus on rare disease diagnosis. He led the formation of the Exome Aggregation Consortium (ExAC), a collection of sequence data from over 60,000 people, which has become a critical resource in clinical genetics. He also co-directs the Broad Institute's Center for Mendelian Genomics, and has led the sequencing of over 3,000 members of families affected by rare disease. He has over 15 years of experience in human genetics, including a Ph.D. from the University of Sydney, Australia, and postdoctoral training in genomics at the Wellcome Trust Sanger Institute in Cambridge, UK.

Peter Mundel, M.D.

Goldfinch Bio

Peter Mundel, M.D.

Senior Vice President of Biology, Goldfinch Bio

Peter Mundel joined Goldfinch Bio after serving as a Consultant to Third Rock Ventures, where he played a leading role in the creation and launch of Goldfinch Bio. Peter brings more than 25 years of experience as a leader in academic research, most recently at Massachusetts General Hospital and Harvard Medical School. A major focus of Peter's work has been the development of precision therapeutics for patients with kidney diseases through a mechanistic understanding of the cell biology and pathology of the kidney, with a focus on podocytes. A pioneer of molecularly targeted treatment for proteinuric kidney disease, Peter has published more than 140 peer-reviewed manuscripts and has given numerous invited lectures nationally and internationally. He is a member of the American Society for Clinical Investigation.

As a recognized leader in the field of nephrology, Peter is the recipient of many awards including the Young Investigator Award from the American Society of Nephrology and the American Heart Association. Peter holds an M.D. from the University of Heidelberg, Germany.

Stefan Somlo, M.D.

Yale School of Medicine

Stefan Somlo, M.D.

C. N. H. Long Professor of Medicine, Professor of Genetics, and Chief of the Section of Nephrology at the Yale School of Medicine

Steve Somlo's research interest over the past 25 years has been to understand the genetic and biological bases of human polycystic kidney and liver diseases. His laboratory began with discovering disease genes for autosomal dominant polycystic kidney disease (PKD2), isolated polycystic liver disease (PRKCSH, SEC63) and recessive polycystic kidney disease (PKHD1). His group used these discoveries as the starting point from which to define both genetic and cellular mechanisms underlying the respective human diseases.

Steve graduated from Harvard College and the College of Physicians and Surgeons of Columbia University. He did his clinical training at the Albert Einstein College of Medicine and Yale and was on faculty at Albert Einstein before returning to Yale. He is a member of the American Society for Clinical Investigation and Association of American Physicians and is a recipient of the Lillian Jean Kaplan International Prize for Polycystic Kidney Disease Research and the Homer W. Smith Award from the American Society of Nephrology.

JOIN THE RENAISSANCE

• Principal/Senior Scientist, Biomarker Translational Research

  The Opportunity

  We’re seeking a highly motivated and technically excellent laboratory Principal Scientist with a strong background in disease characterization and biomarker discovery to join our Translational Medicine Department to contribute to building our discovery pipeline for renal diseases. The successful candidate will focus on the discovery and progression of novel biomarkers and therapeutics for Goldfinch programs. Responsibilities include leading scientific research to identify, evaluate, and characterize relevant urine, blood, or tissue-based biomarkers that will provide useful pharmacodynamic and efficacy endpoints in preclinical and clinical settings.

  Major Responsibilities

  • Develop strategy and scientific approach to identify novel diagnostic, prognostic, and pharmacodynamic biomarkers to enable scientific driven go/no go decisions for programs to assist in program progression.
  • Develop in vitro and biochemical assays to evaluate efficacy, PK/PD relationship, and novel biomarkers to characterize molecules for potential therapeutic effects.
  • Lead the identification and validation of novel biomarkers to enable scientific driven go/no go decisions for programs to assist in program progression.
  • Establish and manage external research collaborations to identify diagnostic and prognostic biomarkers of kidney disease progression.
  • Participate in and lead cross-functional teams to support preclinical drug discovery and development.
  • Prepare, review and deliver high quality scientific presentations for internal/external use.
  • Commitment to help the team achieve deliverables and meet aggressive timelines.

  Requirements and Qualifications

  • EDUCATION
  • M.S. / PhD
  • REQUIRED EXPERIENCE
  • Minimum of 6 years post-degree research in an industry setting.
  • Extensive experience in cellular and biochemical science such as standard molecular biology and protein biochemistry techniques (e.g. cell culture, immunohistochemistry, protein purification, real-time PCR, protein quantification, immunoprecipitation) is required.
  • Experience with mass spectrometry is a plus.
  • Strong publication record and demonstrated experience conducting independent research, preferably in the field of monogenic diseases.
  • KNOWLEDGE SKILLS AND ABILITIES
  • Hands on experience in the development and validation of biomarker assays in the preclinical and clinical setting required.
  • Strong leadership and evidence of strategic scientific thinking.
  • Effective managerial skills and the ability to lead independent scientists with different skill sets.
  • Expertise in cutting edge assay technologies and proven assay troubleshooting skills.

  
  
• Director, Information Technology & Informatics

  The Opportunity

  Goldfinch is seeking an Informatics professional to lead the design, implementation and growth of our information architecture. This individual with manage infrastructure and resources to meet organizational needs and will be responsible for working cross-functionally with all departments to identify long-term, scalable, practical solutions for research and operations as the organization grows. He/she will be expected to establish close partnerships with colleagues from multiple disciplines to translate business needs into state-of-the-art informatics solutions.

  Major Responsibilities

  • LEADERSHIP
  • Provide strong leadership and business acumen, as well as data and analytical skills and relationship-building capabilities to inspire the organization around common goals, vision and values for IT and informatics
  • Define and implement data architecture and company-wide strategy for data storage, processing, analysis and mining
  • Serve as champion for global data management, governance, quality and vendor relationships across the company
  • Establish an architecture and a collection of integrated decision-support applications and databases, providing the company easy access to corporate data
  • Grow the breadth and depth of department expertise to meet short and long-term corporate objectives
  • INFORMATION TECHNOLOGY
  • Oversee contingency planning and IT security and compliance by establishing controls and processes in support of data security, PHI, SOX and other relevant regulatory requirements
  • Manage vendors, consultants and overall budget for data management and IT
  • Lead the planning and estimation of IT &anp; Informatics projects
  • Regularly and effectively communicate with key project stakeholders, keeping them advised of project progress and generally making IT activities transparent to stakeholders
  • Set strategy for IT infrastructure and software capabilities for current and future organizational needs
  • Maintain ongoing knowledge of industry trends and ability to utilize that knowledge to determine the most efficient ways to meet business needs
  • Communicate strategy to scientific personnel, operations and senior management to ensure alignment
  • Measures availability, performance, capacity, and utilization of IT and Informatics services
  • Detects, monitors, reports, manages, escalates and ultimately prevents service failures and/or degradations
  • Take ownership of security across the board and lead IT related compliance for the Company
  • Collaborate with others to facilitate business needs definition, workflow design and integration of scientific processes and technology into effective IT solutions

  Requirements and Qualifications

  • EDUCATION
  • Advanced degree in life sciences
  • REQUIRED EXPERIENCE
  • 7-10 years of relevant experience working in Biotech
  • 5-7 years of experience managing and implementing informatics and IT solutions in a start-up, biotech environment
  • Experience with evaluating, implementing and managing scientific data management platforms, cloud computing (AWS), document control/electronic lab notebook software, on-site storage solutions and IT vendor services
  • Prior experience and record of accomplishment leading cross functional teams and delivering on schedule in a start-up biotech environment
  • Prior experience in successfully implementing, utilizing and leveraging outsourcing strategies
  • KNOWLEDGE SKILLS AND ABILITIES
  • Ability to identify impediments to complex business and research issues and provide timely and cost-effective solutions
  • Solid scientific/ technical knowledge to be able to successfully ensure project scope and fit technology for applications, networking and information systems strategic roadmap and execution of all Informatics solutions and IT services
  • Practical understanding of relational database design and development
  • Demonstrated understanding of the software development lifecycle
  • Ability to adapt to increasing scope and complexity of work brought on by growth/change and helps others manage through change
  • Strong written, oral and public speaking communication skills

  
  
• Senior Research Associate, Biology

  The Opportunity

  The Senior Research Associate will develop, implement and execute in vivo and in vitro assays required for the advancement of high priority projects and Goldfinch Bio's Product Engine.

  Major Responsibilities

  • Development and implementation of a diverse set of cellular assays used to support lead discovery
  • In partnership with scientific leadership design, execute, troubleshoot, and interpret biological experiments in support of program objectives
  • Interact and communicate results and conclusions to the biology team and cross-functional project teams

  Requirements and Qualifications

  • B.S. or M.S. in cell and/or molecular biology or pharmacology
  • 3 to 5 years of industry experience
  • Experience developing cellular assays used to drive early-stage programs towards candidate selection, including miniaturization and automation of high-content imaging, as well as protein and RNA assays
  • Target validation experience with ability to assay target biology with genetic perturbation techniques such as CRISPR-Cas9 and shRNA, in addition to the construction of stable cell lines expressing genes of interest
  • Demonstrated ability to thrive in a team environment
  • Strong experimental background and a rigorous, analytical approach to problem solving
  • Familiarity with high-content phenotypic screening
  • Experience with visualization software and associated analysis of rich cellular datasets
  • Some weekend work will be required

  
  
• Senior Scientist, Biology

  The Opportunity

  The Senior Scientist will play an integral role as a member of Goldfinch's Biology team, focusing on advancing the Company's product engine to identify and validate novel targets to treat kidney disease.

  Major Responsibilities

  • Independently design, execute, troubleshoot, and interpret biological experiments in support of target identification, validation, and lead discovery
  • Prepare SOPs for diverse assays and maintain accurate documentation of experiments
  • Engage and interact with the biology group, cross-functional project teams, and to senior management to discuss experimental results and conclusions

  Requirements and Qualifications

  • Ph.D. in cell and/or molecular biology
  • 3 to 5+ years of relevant industry experience
  • Hands-on, independent experience in diverse in vitro experimental model systems including CRISPR-Cas9, shRNA, and protein expression techniques
  • Proven track record developing cell assays to support optimization of molecules and/or phenotypic screening using high content microscopy or other imaging systems
  • Detailed familiarity with cytoskeletal and/or cell death biology
  • Experience with iPSC/ESC and organoid biology
  • Experience leading drug discovery projects

  
  
• Lead Statistical Geneticist

  The Opportunity

  At the very heart of Goldfinch’s effort to bring precision medicines to kidney disease is our Patient Registry. Through global collaborations and partnerships, we are bringing together patients with FSGS/proteinuria worldwide and building a comprehensive data warehouse containing many thousands of whole genome sequences from patient samples, coupled to deep longitudinal clinical profiles.

  Major Responsibilities

  • We seek a statistical geneticist or biostatistician who is well-versed in analyzing large sets of human genomic and transcriptomic data of complex phenotypes. This lead position is central to the mission of our company and on our critical path to success in the clinic, which will depend on our ability to translate human genetic discoveries in kidney disease into novel therapeutic targets. The individual in this role will work very closely with the heads of biology, preclinical, clinical and computational biology, as well as with our academic founders.
  • Using samples obtained through collaborations and partnerships, this individual will help design a comprehensive clinico-genomics data warehouse of the highest quality. She/he will develop rigorous quality control procedures for whole genome sequences, transcriptomic (RNAseq) data, and longitudinal clinical profiles, and lead studies leveraging best-practice statistical approaches to explore the association of genetic variants with onset and progression of disease with the goal of identifying novel targets for therapeutic intervention. Moreover, she/he will use large-scale transcriptomic data sets from patient tissue to identify gene expression changes associated with disease state which may be useful as clinical biomarkers.
  • The sheer volume of the data generated, and potential impact on a profoundly underserved patient population, makes this an exciting opportunity for a motivated statistical geneticist who wishes to apply the results of genetic investigation to support the discovery of novel precision medicines and lead a renaissance in the treatment of kidney disease.

  Requirements and Qualifications

  • EDUCATION
  • Ph.D. or M.D., Ph.D. in Human Genetics, Epidemiology, Biostatistics, Bioinformatics or related field.
  • REQUIRED EXPERIENCE
  • 2-5 years’ post-degree experience in an academic or industrial setting preferred, but candidates at all levels will be considered.
  • KNOWLEDGE SKILLS AND ABILITIES
  • Solid foundation in statistics and genetics.
  • Experience using large-scale phenotype and genetic data.
  • Knowledge of sequence alignment and variant calling pipelines (BWA, STAR, GATK, etc)
  • Experience using clinical data, electronic medical records, and laboratory data for analysis of complex phenotypes.
  • Experience with RNAseq data analysis and eQTL studies a plus.
  • Knowledge of statistical genetics software (PLINK/SCAT/GAVA).
  • Experience using statistical software (R/MATLAB/SAS).
  • Programming/Scripting skills (Perl/Python/Shell/Java/Linux).
  • Machine learning experience a plus.
  • General knowledge of Cell Biology.
  • Ability to work as part of a highly collaborative team.

  
  
• Lab Manager

  The Company

  Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney disease. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for people with kidney disease. Goldfinch was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass. For more information, please visit www.goldfinchbio.com. At Goldfinch, we’re pioneering a new approach to discover and develop therapeutics that target the molecular basis of kidney disease. Where others see risk, we see opportunity to make an impact and redefine the state of care for patients with kidney disease. We recognize the importance of collaboration, and strive to work alongside patients, clinicians and other partners to empower patients and develop treatments for conditions where no approved therapies exist. We’re looking for teammates who relish the challenge, and are compelled to leave a positive mark on the lives of colleagues and patients alike.

  The Opportunity

  Goldfinch is seeking a Lab Manager to maintain and expand our biology lab including lab supply inventory, procurement, equipment maintenance and safety within our highly collaborative environment. The lab manager will also participate in the execution of in vitro assays required for the advancement of high priority projects and Goldfinch Bio's Product Engine.

  Major Responsibilities

  • Assist in the maintenance and expansion of a biology lab including maintaining an environment of collaboration and creativity that is fundamental to our culture.
  • Think critically to resolve unique issues revolving around a shared work environment.
  • Oversee the maintenance of laboratory supplies, equipment (including laboratory computers), instruments, and service contracts.
  • Manage and oversee the maintenance and repair of laboratory equipment, including daily upkeep, routine quality control and troubleshooting, and scheduling of preventative maintenance.
  • Develop standard operating procedures for the start-up and shutdown of shared equipment.
  • Think critically to resolve unique issues revolving around a shared work environment, equipment usage metrics and calendars.
  • Lead management of alarm systems, including restoration, resets, and routine checks.
  • Develop optimal, cost-effective solutions for use of lab reagents and operation of equipment.
  • Manage procurement (including negotiation), shipping, and receiving.
  • Establish and maintain relationships with vendor representatives.
  • Working closely with business and operations team to drive contracts to resolution and execution.
  • Manage and oversee the inventory management control program.
  • Ensure safe and efficient laboratory operations.
  • Manage chemical inventories and work with EHS consultants to manage liquid and solid waste pickup and storage of chemical and biohazard waste.

  Requirements and Qualifications

  • EDUCATION
  • BS in a science related discipline.
  • At least 2 years’ experience in lab operations/management; ideally in industry.
  • REQUIRED EXPERIENCE
  • At least 5 years’ lab experience.
  • KNOWLEDGE SKILLS AND ABILITIES
  • Outstanding organizational skills and ability to prioritize multiple tasks and/or projects· Knowledge of MS Office (Excel, Outlook, Publisher, PowerPoint), proficiency with database systems.
  • Strong communication, collaboration, problem solving, and negotiation skills.
  • Aseptic technique for cell culture.
  • Some weekend work will be required.